DrugBiological
Pembrolizumab clinical trials
Also written Keytruda, MK-3475, SCH 900475 and Lambrolizumab.
- studies test it
- 1,745
- open now
- 415
- in phase 3
- 171
- first study started
- 2010
Keep track of what changes. Save the pembrolizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Pembrolizumab
- 1,440
Brand
- Keytruda
- 943
Development codes
Other names
Combined with it in one product
Biosimilars in development
- QL2107
- 10
- RPH-075
- 5
- BCD-201
- 4
- SB27
- 2
- GME751
- 2
Studies by the year they started
1,741 studies that test it; most in 2017 (198); 4 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 10 |
| 2014 | 26 |
| 2015 | 86 |
| 2016 | 153 |
| 2017 | 198 |
| 2018 | 166 |
| 2019 | 151 |
| 2020 | 152 |
| 2021 | 159 |
| 2022 | 177 |
| 2023 | 133 |
| 2024 | 119 |
| 2025 | 109 |
| 2026 | 98 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 30
- Phase 1
- 645
- Phase 2
- 1,162
- Phase 3
- 171
- Phase 4
- 9
- No phase
- 16
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 127
Who runs them
Industry 590 · Other 1,155
Merck Sharp & Dohme LLC (183) · M.D. Anderson Cancer Center (64) · National Cancer Institute (NCI) (54) · Memorial Sloan Kettering Cancer Center (32) · Dana-Farber Cancer Institute (26) · Mayo Clinic (24) · University of Chicago (19) · Emory University (18)
Often tested with
Tested in the same studies.
Lenvatinib (89) · Carboplatin (66) · Paclitaxel (66) · Nivolumab (52) · Cisplatin (47) · Olaparib (35) · Gemcitabine (31) · Bevacizumab (28)
Studies
Open first, then newest update. How each study uses pembrolizumab is read from its arms, and is right about nine times in ten.
Testing it · 1,745
- Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)Not yet recruitingPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT07388550Written as Keytruda
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Pembrolizumab
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingPhase 3National Cancer Institute (NCI)NCT06422806Written as Pembrolizumab
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT01174121Written as Pembrolizumab (Keytruda)
- The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III MelanomaRecruitingPhase 2Primmune Therapeutics, Inc.NCT07565285Written as Pembrolizumab
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07198074Written as Pembrolizumab
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07667335Written as Pembrolizumab
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingPhase 2Astellas Pharma Global Development, Inc.NCT07475806Written as Pembrolizumab
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerRecruitingPhase 2Solstice Oncology, Inc.NCT07808151Written as Pembrolizumab
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/2Daiichi SankyoNCT07890714Written as Pembrolizumab
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07886905Written as Pembrolizumab
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT04421560Written as Pembrolizumab
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT04671667Written as Pembrolizumab
- IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)RecruitingPhase 1TuHURA Biosciences, Inc.NCT06940440Written as Pembrolizumab
- Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingPhase 2University Hospital, Basel, SwitzerlandNCT07840456Written as Pembrolizumab
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Merus B.V.NCT03526835Written as MCLA-158 + Pembrolizumab
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingPhase 1/2AbbVieNCT06772623Written as Pembrolizumab
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Michael Spinner, MDNCT07021989Written as Pembrolizumab
- A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsRecruitingPhase 3AbbVieNCT07756645Written as Pembrolizumab
- Histotripsy in Biliary Tract CancerRecruitingNot applicableNYU Langone HealthNCT07853690Written as Pembrolizumab
See all 1,745 studies that test pembrolizumab →
Given in every arm · 561 — pembrolizumab is usual care beside what is tested
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingPhase 3National Cancer Institute (NCI)NCT06589804Written as Pembrolizumab
- Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLRecruitingPhase 1Dana-Farber Cancer InstituteNCT06475235Written as Pembrolizumab
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Pembrolizumab
- Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03618550Written as pembrolizumab
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06899126Written as pembrolizumab
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Carboplatin + Pemetrexed + Pembrolizumab
- Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsRecruitingPhase 1Gilead SciencesNCT07128303Written as Pembrolizumab
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Pembrolizumab
- Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or MetastaticRecruitingPhase 1Sutro Biopharma, Inc.NCT07807345Written as Pembrolizumab
- Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 2Canadian Cancer Trials GroupNCT07890493Written as Pembrolizumab
- Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 1/2VA Office of Research and DevelopmentNCT07889232Written as Pembrolizumab
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Pembrolizumab
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingPhase 1Eli Lilly and CompanyNCT06465069Written as Pembrolizumab
- A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaRecruitingPhase 1/2Tvardi Therapeutics, IncorporatedNCT05440708Written as Pembrolizumab
- A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsRecruitingPhase 1/2Astellas Pharma Global Development, Inc.NCT07287995Written as Pembrolizumab
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingPhase 1/2Aminex Therapeutics, Inc.NCT07287917Written as Pembrolizumab
- A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07673887Written as Pembrolizumab
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07061977Written as Pembrolizumab
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Pembrolizumab
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsRecruitingPhase 1Vividion Therapeutics, Inc.NCT06004245Written as Pembrolizumab
Showing 20 of 561.
As the comparator · 100 — what is tested is compared with pembrolizumab
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386Written as Pembrolizumab
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingPhase 3AmgenNCT05920356Written as Pembrolizumab
- A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)RecruitingPhase 3Bristol-Myers SquibbNCT07361510Written as Pembrolizumab
- A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.Not yet recruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT07876414Written as Pembrolizumab
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingPhase 3AstraZenecaNCT06764875Written as Pembrolizumab
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingPhase 2/3BioNTech SENCT06712316Written as Pembrolizumab
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingPhase 3BayerNCT06452277Written as Pembrolizumab
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Pembrolizumab
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingPhase 3Boehringer IngelheimNCT07195695Written as Pembrolizumab
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingPhase 2/3Mirati Therapeutics Inc.NCT04613596Written as Pembrolizumab
- A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3Hoffmann-La RocheNCT07541170Written as Pembrolizumab
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerNot yet recruitingPhase 3PfizerNCT07578649Written as Pembrolizumab
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)Not yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07793942Written as Pembrolizumab
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 3PfizerNCT07222566Written as Pembrolizumab
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingPhase 3AstraZenecaNCT06103864Written as Pembrolizumab
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerRecruitingPhase 3AstraZenecaNCT06868277Written as Pembrolizumab
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT06357533Written as Pembrolizumab
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCRecruitingPhase 3AstraZenecaNCT06627647Written as Pembrolizumab
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingPhase 3RemeGen Co., Ltd.NCT07315750Written as Pembrolizumab
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 3AstraZenecaNCT06692738Written as Pembrolizumab
Showing 20 of 100.
Codes
What other systems call pembrolizumab · ClinicalTrials.gg INT006316
- MeSH (NLM) C582435pembrolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) DPT0O3T46PPEMBROLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1547545Confirmed FDA, Wikidata
- Wikidata Q13896859pembrolizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C106432PembrolizumabOne source FDA
- DrugBank DB09037One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582435 | pembrolizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | DPT0O3T46P | PEMBROLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1547545 | — | Confirmed FDA, Wikidata |
| Wikidata | Q13896859 | pembrolizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C106432 | Pembrolizumab | One source FDA |
| DrugBank | DB09037 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.